Dr Reddy Laboratories Secures Licensing Accord with Gilead for Long Acting HIV Therapy

Hyderabad-based pharmaceutical major Dr Reddy Laboratories has entered into a formal licensing agreement with Gilead Sciences to produce the long-acting HIV therapy lenacapavir. The therapeutic represents a generational shift from daily oral regimens to biannual or annual subcutaneous injections. This accord positions the Indian manufacturer as a key supplier for low- and middle-income countries. The negotiation process involved intricate intellectual property safeguarding and technology transfer protocols to ensure generic affordability without compromising manufacturing standards. Regulatory bodies must now fast-track bioequivalence trials to clear the drug for commercial distribution. The partnership reflects the growing dominance of Indian contract manufacturers in global health supply chains. The ultimate beneficiaries are hundreds of thousands of HIV-positive individuals across developing nations who will gain access to revolutionary treatment compliance options. For Dr Reddy, the contract diversifies its revenue streams away from traditional generic molecules toward high-margin specialty therapeutics. The arrangement sets a precedent for how pharmaceutical giants license breakthrough drugs to the Global South.